FIELD: pharmacology.
SUBSTANCE: invention relates to a compound having the systematic name 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy) benzamide (compound 1) in the form of a free base crystalline anhydrate, a free base hydrate of crystalline form, a solvate of crystalline form, a hydrochloride salt of crystalline form, or a sulfate salt of crystalline form. The invention also relates to a pharmaceutical composition having an inhibitory activity against anti-apoptotic proteins of the Bcl-2 family comprising a therapeutically effective amount of the compound of the invention and one or more pharmaceutically acceptable excipients.
EFFECT: crystalline forms of compound 1 suitable for use as an active pharmaceutical ingredient.
21 cl, 14 dwg, 14 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR TREATMENT OF BCL-2 PROTEIN RELATED DISEASES | 2010 |
|
RU2551376C2 |
| PARECOXIB SODIUM CRYSTALLINE SALT | 2003 |
|
RU2300529C2 |
| SALTS AND POLYMORPHIC MODIFICATIONS OF THE INHIBITOR VEGF-R | 2006 |
|
RU2369607C1 |
| SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-cd]INDOL-6-ONE | 2011 |
|
RU2570198C2 |
| SOLID FORMS OF SELECTIVE CDK4/6 INHIBITOR | 2014 |
|
RU2619944C2 |
| CO-CRYSTALLINE FORMS OF TRAMADOL AND NSAID | 2009 |
|
RU2599717C2 |
| CRYSTALLINE PYRIMIDINYL-3,8-DIAZABICYCLO[3.2.1]OCTANYLMETHANONE AND ITS APPLICATIONS | 2020 |
|
RU2803145C2 |
| ISETHIONATE SALT OF CDK4 SELECTIVE INHIBITOR | 2004 |
|
RU2317296C2 |
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| NOVEL SALT AND MEDICAL APPLICATION | 2012 |
|
RU2609011C2 |
